Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's and Parkinson's Diseases at AD/PD™ 2024 International Conference [Yahoo...
Athira Pharma, Inc. (ATHA)
Company Research
Source: Yahoo! Finance
neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and dementia with Lewy bodies Results from exploratory SHAPE Phase 2 trial show encouraging safety and pro-cognitive measures with fosgonimeton treatment and underscore confidence in Phase 2/3 LIFT-AD trial with data anticipated in the second half of 2024 BOTHELL, Wash., March 08, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, presented new clinical and preclinical data further highlighting the therapeutic potential of fosgonimeton at the AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders, being held in Lisbon, Portugal March 5 – 9, 2024. Fosgonimeton is a potentially first-in-class investigational small molecule designed to positively modulate the hepatocyte growth factor (HGF) system, whic
Show less
Read more
Impact Snapshot
Event Time:
ATHA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATHA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATHA alerts
High impacting Athira Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
ATHA
News
- One Athira Pharma Insider Raised Their Stake In The Previous Year [Yahoo! Finance]Yahoo! Finance
- Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer [Yahoo! Finance]Yahoo! Finance
- Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical OfficerGlobeNewswire
- Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease [Yahoo! Finance]Yahoo! Finance
- Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s DiseaseGlobeNewswire
ATHA
Earnings
- 11/9/23 - In-Line
ATHA
Sec Filings
- 4/16/24 - Form 4
- 4/16/24 - Form 3
- 4/9/24 - Form ARS
- ATHA's page on the SEC website